SHAREHOLDER ALERT:  Pomerantz Law Firm Reminds

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2022
206
SHAREHOLDER ALERT:  Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Amarin Corporation plc of Class Action Lawsuit and Upcoming Deadline – AMRN  

NEW YORK, April 07, 2019 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Amarin Corporation plc (“Amarin” or the “Company”) (NASDAQ:  AMRN) and certain of its officers.  The class action, filed in United States District Court, District of New Jersey, and indexed under 19-cv-08423, is on behalf of a class consisting of all persons other than Defendants who purchased or otherwise acquired the publicly traded securities of Amarin Corporation plc (“Amarin” or the “Company”) between September 24, 2018 and November 9, 2018 (the “Class Period”), who were damaged thereby seeking to pursue remedies under the Securities Exchange Act of 1934 (the “Exchange Act”).

If you are a shareholder who purchased Amarin securities between September 24, 2018, and November 9, 2018, both dates inclusive, you have until April 23, 2019, to ask the Court to appoint you as Lead Plaintiff for the class.  A copy of the Complaint can be obtained at www.pomerantzlaw.com .  To discuss this action, contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888.476.6529 (or 888.4-POMLAW), toll-free, Ext. 9980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased. 

[Click here to join this class action]

Amarin is a biotechnology company. Amarin’s REDUCE-IT cardiovascular outcomes study commenced in 2011.  It enrolled and followed 8,179 randomized patients, and was conducted based on a special protocol assessment agreement with the United States Food and Drug Administration (“FDA”).

REDUCE-IT was the first global cardiovascular outcomes study to prospectively evaluate the effect of Vascepa, or any therapy, in adult patients with both LDL-cholesterol (“LDL-C”) controlled to between 41-100 mg/dL (median baseline 75 mg/dL) by statin therapy and various cardiovascular risk factors, including persistent elevated triglycerides (“TGs”) between 150-499 mg/dL (median baseline 216 mg/dL).  In addition, the primary prevention cohort had diabetes mellitus and at least one other cardiovascular risk factor, while the secondary prevention cohort had established cardiovascular disease.

The complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements regarding the Company’s business, operational and compliance policies.  Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (1) the top-line results Amarin touted about its REDUCE-IT trial for Vascepa were not as positive as the company represented; (2) the placebo given to patients in the control arm of REDUCE-IT may have increased the incidence of cardiovascular events in those patients; (3) as a result, Amarin's public statements were materially false and misleading at all relevant times.

On November 10, 2018, scientists that conducted the REDUCE-IT trial presented the full results of that study at the Scientific Sessions of the American Heart Association in Chicago, Illinois.  In that presentation, the scientists disclosed for the first time “bad” LDL cholesterol levels rose three percent in the Vascepa patients and ten percent in the placebo patients.  Other markers of blood fat were also higher in the placebo patients.  These data raised concerns that the mineral oil placebos might be interfering with the background regimen of cholesterol-lowering statins that all the patients in the study were taking.  The 10% increase in LDL cholesterol might have led to more adverse cardiovascular events among placebo patients.

As a result of these disclosures, the price of Amarin’s common stock dropped from $21.05 per share to $15.38 per share in two trading days, a decrease of approximately 27%.

The Pomerantz Firm, with offices in New York, Chicago, Florida, and Los Angeles, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com

CONTACT: Robert S. Willoughby Pomerantz LLP rswilloughby@pomlaw.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Ajman Forum Puts Algorithmic Messaging Under Scrutiny

Updated Category News Views 11

Algorithms do not merely shuffle posts anymore; they can scramble confidence in the institutions people depend on. That was the serious undercurrent at Ajman Media Forum 2026 – THE SIGNAL, where a session on who leads the government message in an algorithm-driven age brought the discussion back to an uncomfortable reality: communication, cybersecurity and social...

Continue Reading
MetaComp's $10M Extension Tests Stablecoin Rails in Trade

Updated Category News Views 59

A ten-million-dollar check is cheap until the licensing bills start arriving. MetaComp has added roughly US$10 million from Tether and Abu Dhabi-based Further Asset Management, taking its Pre-A and Pre-A+ fundraising to about US$45 million. The important bit is not the headline-sized pile of cash. It is where management says the money is going: licences, compliance...

Continue Reading
LGT Middle East Win Highlights Patient Private Banking

Updated Category News Views 44

A trophy in Dubai is not a balance sheet, but it can be a useful calling card when the clientele measures relationships in decades rather than quarters. LGT Middle East was named Best Pure Play Private Bank at the WealthBriefing MENA Awards 2026, at a ceremony held in Dubai on November 18. For a family-owned wealth manager working with Middle Eastern families, that sort...

Continue Reading
APEC in Shenzhen Puts Trade Openness Back in Focus

Updated Category News Views 68

Shenzhen is hosting a familiar but consequential argument: prosperity gets harder to share when trade channels clog up. At the 33rd Asia-Pacific Economic Cooperation Economic Leaders' Meeting on November 18, President Xi Jinping used the opening of the APEC CEO Summit to argue for peace, openness, innovation, mutual benefit and support for the WTO-centered multilateral...

Continue Reading
SAGA's Radar Assays Tighten the Trapper North Case

Updated Category News Views 210

Rock that keeps showing up where the model says it should is the sort of boring news a junior miner desperately needs. SAGA Metals has put out fresh assay results from Radar’s Trapper North area, and the useful part is not merely a loud grade in one hole. It is the apparent persistence of thick titanium-vanadium-iron oxide mineralization across tighter-spaced drilling....

Continue Reading
IQSTEL’s 2027 Plan Has Scale but Still Needs Proof

Updated Category News Views 18

A $313 million nine-month revenue figure gets attention, yet this story is really about whether IQSTEL can finally turn a big telecom pipe into money that sticks. The company grew consolidated revenue 34.5% year over year through September 30, 2026, and third-quarter revenue hit $106.0 million, its second straight quarter above $100 million. That is real operating scale,...

Continue Reading
Lake Ridge Sets $0.68 Dividend as 2026 Payouts Rise

Updated Category News Views 128

A community bank raising its cash return is not fireworks, but it gets my attention faster than another glossy growth slogan. Lake Ridge Bancorp has declared a fourth-quarter 2026 dividend of $0.68 per share, payable December 16 to shareholders of record on November 30. That is a plain, useful announcement from OTCQX:LRBI, and plain is often underrated when you are...

Continue Reading
Katahdin's Portland Branch Bet Moves Downtown in 2027

Updated Category News Views 159

Exchange Street is getting a real-world vote of confidence, and that is more interesting than another app update ever will be. Katahdin Trust intends to open a full-service branch at 120 Exchange Street in downtown Portland, with renovations slated to begin early in 2027 and an opening expected later that year. For a Maine community bank with nearly $1.2 billion in...

Continue Reading
Endeavor Metals Makes Its Case for Clearer Bullion

Updated Category News Views 27

Gold buyers do not need another velvet-rope sales pitch; they need the math before the handshake. Endeavor Metals Group, a West Palm Beach dealer established in 2013, is pitching something more useful than grand prophecy: a staffed, consultative route into physical gold, silver, platinum, palladium, bullion and collectible coins. In a business where shiny inventory can...

Continue Reading
Jumia’s Breakeven Retreat Invites Legal Scrutiny

Updated Category News Views 154

Jumia’s credibility problem did not arrive wearing a disguise. The company spent much of 2026 telling investors that a fourth-quarter Adjusted EBITDA breakeven was still on the table, then discarded that target after reporting third-quarter results. For holders of NYSE:JMIA, that kind of reversal stings because the promise was not some stray talking point; it was...

Continue Reading

Top 5 Most Recently Viewed Articles

New York Times: Strong Growth Ahead with Innovative Strategies

Updated Category News Views 103

New York Times Positioned for Future Profit Growth Recently, Deutsche Bank has taken a significant step by initiating coverage on shares of the New York Times (NYSE:NYT) with a promising Buy rating and a price target of $65.00. Their analysis highlights the media company's innovative digital-first subscription model and strong fundamentals as major drivers of growth and...

Continue Reading
Maximizing Opportunities in Today's Commercial Insurance Market

Updated Category News Views 151

Understanding the Current U.S. Commercial Insurance Landscape In today’s economic climate, U.S. commercial insurance buyers are navigating one of the most advantageous periods witnessed in recent years. Despite this promising environment, the looming uncertainties affecting the economy pose challenges that require careful consideration from both buyers and insurers...

Continue Reading
Understanding the Market Activity of Dowlais Group Plc Deals

Updated Category News Views 179

Key Information About Dowlais Group Plc This disclosure pertains to an exempt principal trader engaged in client-serving transactions involving Dowlais Group Plc, providing essential insights into the movements and transactions related to its shares. Notable Dealings by the Exempt Principal Trader As highlighted, important dealings regarding the ordinary shares of Dowlais...

Continue Reading
Golden State Dermatology's Smart Expansion into Los Altos

Updated Category News Views 20

Golden State Dermatology Welcomes Todd Anhalt The Bay Area’s dermatology landscape just got an intriguing development. Todd Anhalt, a veteran dermatologist with a track record as long as a roll of duct tape, has teamed up with Golden State Dermatology (GSD). This Los Altos partnership isn't just about slapping a new name on a door—it's a strategic move to bolster...

Continue Reading
Unlocking Tesla's Future: AI, Innovation, and Growth Strategies

Updated Category News Views 117

Tesla got itself into a tight spot back in the day, trading around 40% lower than its peak. Folks were already getting antsy about where the stock was heading—had to keep an eye on those quarterly delivery numbers. The car side of things? Over 80% of projected revenues for FY24 came straight from that segment, so if it tanked, so did the whole show. Tesla's Valuation...

Continue Reading